UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007130
Receipt number R000008396
Scientific Title A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.
Date of disclosure of the study information 2012/01/24
Last modified on 2021/02/01 18:26:09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.

Acronym

Prospective evaluation of eGFR in CKD with nephrosclerosis by lipid intervention study (LAKE study)

Scientific Title

A multicenter randomized study evaluating the efficacy and safety of HMG-CoA reductase inhibitors (statins) in dyslipidemic patients with nephrosclerosis.

Scientific Title:Acronym

Prospective evaluation of eGFR in CKD with nephrosclerosis by lipid intervention study (LAKE study)

Region

Japan


Condition

Condition

Nephrosclerosis

Classification by specialty

Medicine in general Cardiology Endocrinology and Metabolism
Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study is to investigate the effect of statins on dyslipidemic patients with nephrosclerosis.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

An absolute change of estimated glomerular filtration rate

Key secondary outcomes

1. An absolute change of renal function
-urinary albumin or protein, serum creatinine, urinary beta 2 microglobulin(BMG), urinary N-acetyl-beta-D-glucosaminidase(NAG)
2. An absolute change of serum lipids
-TC, LDL-C, TG, HDL-C, non HDL-C, apolipoprotein(Apo A-I, Apo A-II, ApoB)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking


Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Pitavastatin group

Interventions/Control_2

Control group

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Nephrosclerotic patients whose serum LDL-C levels are lower than the levels of management goals recommended by guidline
2. eGFR<60mL/min/1.73m2
3. Proteinuria<0.5g/day(or <0.5g/gCr)
4. HbA1c<6.5%(NGSP)
5. Patients 20 years or older at the time of provision of consent
6. Patients who are treated with anti-hypertensive drugs

Key exclusion criteria

1. Patients who are treated with statins
2. Patients who are planned to start or change medication for renal disease
3. Severe hypertensive patients (SBP>=150mmHg or DBP >=90mmHg)
4. Severe hepatic dysfunction
5. Abnormal values of serum creatinine caused by any disease except renal disease
6. BMI>25(kg/m2)
7. Patients with thyroid dysfunction
8. History of acute myocardial infarction or stroke during three months prior to the registration
9. Pregnant, breast feeding, or could be pregnant
10. Patients who do not accept informed consent
11. Patients judged as being inappropriate for this study by investigators

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Tsuguru
Middle name
Last name Hatta

Organization

Omihachiman Community Medical Center

Division name

Division of Nephrology

Zip code

523-0082

Address

1379, Tsuchida-cho, Omihachiman- shi, Siga 523-0082, Japan

TEL

0748-33-3151

Email

tsuguhatta@hotmail.com


Public contact

Name of contact person

1st name Tsuguru
Middle name
Last name Hatta

Organization

Omihachiman Community Medical Center

Division name

Division of Nephrology

Zip code

523-0082

Address

1379, Tsuchida-cho, Omihachiman- shi, Siga 523-0082, Japan

TEL

0748-33-3151

Homepage URL


Email

tsuguhatta@hotmail.com


Sponsor or person

Institute

Omihachiman Community Medical Center

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Nagahama City Hospital
Nagahama red cross Hospital
Kotou Memorial Hospital
Hashimoto Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Omihachiman Community Medical Center

Address

1379, Tsuchida-cho, Omihachiman- shi, Siga 523-0082, Japan

Tel

0748-33-3151

Email

030202@city.omihachiman.lg.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

市立長浜病院(滋賀県)
長浜赤十字病院(滋賀県)
湖東記念病院(滋賀県)
橋本医院(滋賀県)


Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 24 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled

77

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2011 Year 05 Month 30 Day

Date of IRB

2011 Year 06 Month 01 Day

Anticipated trial start date

2011 Year 06 Month 01 Day

Last follow-up date

2015 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 01 Month 24 Day

Last modified on

2021 Year 02 Month 01 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008396


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name